01
01 / Origin
Discontinued peptides. Revived.
Pharma sits on libraries of peptide assets — clinically proven, discontinued for business reasons, not biology.
A programmable-biology company
// XV · IV · MMXXVI
We program
biology.
General Biotechnologies manufactures peptide therapeutics at a fraction of the current cost by genetically programming edible microbes to synthesise complex molecules.
ScrollExplore
University of Oxford
Horizon Europe · $4M
Featured in BBC · The Guardian · SynBioBeta
GB-01Manifesto
“Where do I think the next amazing revolution is going to come? For the very first time in our history, biology has the opportunity to be engineering, not science.”
// JENSEN HUANG — CEO, NVIDIA
Design
compile
Deploy
living systems
Design
compile
Deploy
living systems
Edible microbes = drug delivery systems.
GB-02 // Platform
Living cells have their own programming language. We decipher it, then write new code into edible microbes — taking control of their biosynthetic machinery. The cell synthesises complex molecules on demand. The microbe becomes a 2-in-1 peptide factory and delivery vehicle.
PL-01Flagship
Oral GLP-1 · Regenesis™
PL-01Regenesis™
A daily powder.
Injection-free GLP-1. An edible powder that delivers the full-length peptide into the bloodstream at a fraction of the cost.
Explore Regenesis →
PL-02Platform
Reformulation platform
PL-02Pharma partnership
Discontinued peptides. Revived.
A partnership engine for pharma. We resurrect older-generation, off-patent peptides — reformulated as low-cost oral drugs.
PL-03Infrastructure
Biomanufacturing reimagined
PL-03Field-deployable
Pharma, anywhere.
Scaled-down biomanufacturing kits. Programmable microbes that synthesise precise molecules in austere and contested environments.
PL-04R&D
Frontier technologies
PL-04R&D
Moonshots.
Internal R&D at the intersection of human enhancement and longevity.
Flagship — GB-03
Regenesis™
The world's first oral GLP-1 — made by, and delivered inside, an edible microbe. A single-dose daily powder. No cold chain. No needle. Peptides democratised.
Route20g · powder
Target price cap< US$ 5/dose
StageIn Development
Closes in
03:06:26:58
Our goals
0%
of the peptide protected from stomach acid and enzymes (lab-validated).
0mg
of peptide delivered per dose.
Real drugs.
Existing drugs. Remade in microbes. Not supplements.
0
peptide variants in pre-clinical testing — our own novel variants and already-approved GLP-1s.
Bay 01
GB-047
pH 8.2
28.4°C
GB-047
pH 8.2
28.4°C
LED 4,200 lx
OD₇₅₀ 1.42
CO₂ 0.3%
12h · 12h
OD₇₅₀ 1.42
CO₂ 0.3%
12h · 12h
January 2027 · Manufacturing Partnership
10,000 L Manufacturing Pilot — the first robotic cGMP-grade production of oral peptides.
GB-04 // Reformulation Platform/ 04
Peptides given a second life.
Deprioritised assets that are clinically proven but discontinued for business reasons, are given a second life as an oral drug.
02
02 / Option Agreement
Sequence, optioned.
We request the rights to work with the shelved patented asset. In exchange the firm receives a right of first refusal to acquire or license the new oral product.
03
03 / Programme
Edible microbe makes the drug.
Our platform synthesises their drug molecule inside our programmable microbe.
04
04 / Produce
Identical peptide. Fraction of the cost.
The identical peptide, produced at high yield inside our programmable microbe — at a fraction of the cost.
05
05 / Prove
A new preclinical drug asset.
We conduct PK/PD animal studies to demonstrate that the drug successfully gets to the blood using our delivery approach. We also provide a report on the cost of making this drug as an oral formulation.
06
06 / License
Back to pharma.
A novel oral drug asset, returned to the pharma sponsor.
GB-05Biomanufacturing reimagined
Biomanufacturing reimagined: building the 3D printer for biology.
Biology is all around us. From skin bacteria to plants that make thousands of bioactive compounds, the cell is the smallest unit performing sophisticated molecular transformation in the physical world. Genetic engineering gives us the command line for biology.
Our biomanufacturing manifesto
01 —
The story of biotechnology
2026 · present day
10,000 BC
01
Agriculture
Humanity's first biotechnology. Farming molecules from plants — limited to what they are naturally programmed to make.
3000 BC
02
Fermentation
5,000 years of fermentation added a layer of deliberate control — pairing specific yeasts with ingredients to transform one chemical into another.
1953
03
Discovery of DNA
Watson, Crick & Franklin reveal the blueprint — biology finally has a readable grammar.
1978
04
Genentech makes insulin from bacteria
Another layer of control: inserting genes into bacteria and yeast to brew drug molecules like insulin.
2012
05
CRISPR
Programmable molecular scissors. The genome becomes editable code — unlocking precision cures, climate-resilient crops, and designed living systems.
2020s
06
The era of programmable biology
AI tools, multi-omics datasets and computational biology accelerate drug discovery, protein engineering and strain engineering.
Drag · scroll · or use arrows
4 / 6
02 —
The roadmap to biomanufacturing abundance.
01
2030s →
Expansion in microbes
Programming thousands of cell lines from nature — not a handful — into fit-for-purpose manufacturing chassis. Starting with cyanobacteria.
02
2030s →
Bioreactors reimagined.
Bioreactors that can go anywhere and manufacture safely outside of a lab or cleanroom.
03
2030s →
Expansion in biochemistry
Expanding the sophisticated chemistry that a programmed cell can perform.
“
Collaborate with us
→
We invite FROs, startups and non-profits who are working on complementary technologies to collaborate with us.
GB-06Frontier Technologies
Coming soon.
Moonshot programmes at the frontier of human biology.
Subscribe · be the first to know.